Xencor to Present at Upcoming Investor Conferences

Contacts

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

  • TD Cowen 44th Annual Health Care Conference


    Date: Wednesday, March 6, 2024


    Presentation Time: 12:50 p.m. ET / 9:50 a.m. PT


    Location: Boston





  • Leerink Partners Global Biopharma Conference


    Date: Tuesday, March 12, 2024


    Presentation Date/Time: Wednesday, March 13, 2024, 9:20 a.m. ET / 6:20 a.m. PT


    Location: Miami





  • Jefferies Biotech on the Bay Summit


    Date: Wednesday, March 13, 2024


    Location: Miami





  • Barclays Global Healthcare Conference


    Date: Thursday, March 14, 2024


    Presentation Time: 11:15 a.m. ET / 8:15 a.m. PT


    Location: Miami

Live webcasts of the Cowen, Leerink and Barclays presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor’s XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.